ClinicalTrials.gg
RecruitingNCT06508164CRDS RegistryUpdated Sep 28, 2026

International CRDS Registry

An observational study in Calcium Release Deficiency Syndrome, sponsored by Population Health Research Institute. Recruiting at 22 sites in 8 countries. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Population Health Research Institute · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Sep 28, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Sex
All
01

Study summary

Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.

Read the detailed description

Calcium Release Deficiency Syndrome (CRDS) is a recently discovered inherited arrhythmia syndrome that predisposes to malignant ventricular arrhythmias and sudden cardiac death (SCD). The underlying genetic culprit of CRDS is RYR2, which encodes the cardiac ryanodine receptor. In contrast to Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), which stems from pathogenic RYR2 gain-of-function, CRDS manifests secondary to RyR2 loss-of-function. Enrolment into the CRDS registry requires that the putative disease causing RYR2 variant is confirmed to result in a loss-of-function on in vitro functional analysis. Individuals possessing an RYR2 truncating variant or large copy number variant will be eligible for enrolment into a second registry arm. Patients with a suspected CRDS diagnosis whose RYR2 variant is found not to impact function will be entered into a control arm of the registry.

Given its recent discovery, our understanding of CRDS remains in its infancy. The International CRDS registry has been designed to facilitate evaluation of large numbers of CRDS patients and enable robust insights to hopefully improve management of affected patients and families.

02

Conditions studied

  • Calcium Release Deficiency Syndrome
03

In context

Lead sponsor

Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The registry will enrol 3 separate cohorts. The primary cohort consists of CRDS cases. A CRDS case is defined as an individual that possesses a rare RYR2 variant proven to be loss-of-function on in vitro analysis. A second cohort consists of individuals that possess a rare RYR2 truncating variant or large copy number variant. The third cohort involves individuals suspected of having CRDS, however in vitro analysis revealed that their rare RYR2 variant did not impact function.

Eligibility criteria

CRDS Cohort

Inclusion Criterion:

- Presence of a rare* RYR2 variant that is characterized to be loss-of-function based on in vitro testing#

RYR2 Truncating and Large CNV Cohort

Inclusion Criterion:

- Presence of a rare* RYR2 truncating variant and/or large copy number variant involving the RYR2 gene.

Carriers of a Non-Functional RYR2 variant

Inclusion Criterion:

- Presence of a rare* RYR2 variant that is characterized to be neither loss- nor gain-of-function based on in vitro testing#

*rare defined as gnomAD prevalence \< 0.1%

#RYR2 in vitro functional testing will be performed in the laboratory of Dr. Wayne Chen (University of Calgary)

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
26 Years
Patient registry
Yes

Groups and cohorts

  • CRDS

    Possesses a rare RYR2 variant characterized to be loss-of-function based on in vitro testing consistent with a CRDS diagnosis

  • Carrier of an RYR2 truncating variant or large copy number variant

    Possesses a rare RYR2 truncating variant and/or large copy number variant involving the RYR2 gene.

  • Carrier of a non-functional RYR2 rare variant

    Possesses a rare RYR2 variant that is NOT loss-of-function based on in vitro testing and has a clinical phenotype that was considered compatible with CRDS

06

What researchers measure

Primary outcomes

  1. Malignant Ventricular Arrhythmia

    Composite of malignant syncope, ICD shock, cardiac arrest, and sudden cardiac death

    Time frame: 5 years

07

Study locations

22 of 22 sites recruiting
  • University of California
    San Francisco, California 94143, United States
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Vasanth Vedantham, MD, PhD · Principal investigator
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • John Giudicessi, MD, PhD · Principal investigator
  • Duke University
    Durham, North Carolina 27710, United States
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Andrew Landstrom, MD, PhD · Principal investigator
  • Inova Health Care Services
    Fairfax, Virginia 22031, United States
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Robert Przybylski, MD · Principal investigator
  • Garvan Institute of Medical Research
    Darlinghurst, New South Wales 2010, Australia
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Jodie Ingles, PhD, MPH · Principal investigator
  • Antwerp University Hospital
    Edegem, Antwerp 2650, Belgium
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Johan Saenen, MD, PhD · Principal investigator
  • Universitair Ziekenhuis Brussel
    Brussels, 1090, Belgium
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Luigi Pannone, MD · Principal investigator
  • University of Calgary
    Calgary, Alberta T2N 1N4, Canada
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Erkan Ilhan, MD · Principal investigator
  • Alberta Health Services
    Edmonton, Alberta T6G 2C8, Canada
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Joseph Atallah, MD CM, MSc · Principal investigator
  • Children's & Women's Health Centre of British Columbia
    Vancouver, British Columbia V6H 3N1, Canada
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Shubhayan Sanatani, MD · Principal investigator
  • The University of British Columbia
    Vancouver, British Columbia V6T 1Z3, Canada
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Thomas M Roston, MD · Principal investigator
  • Hamilton General Hospital
    Hamilton, Ontario L8L 2X2, Canada
    Recruiting
    • · Contactcrds@phri.ca · 905-521-2100
    • Jason D Roberts, MD MAS · Principal investigator
  • London Health Sciences Centre - University Hospital
    London, Ontario N6A 5A5, Canada
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Habib R Khan, MD · Principal investigator
  • Ottawa Heart Institute
    Ottawa, Ontario K1Y 4W7, Canada
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Simon Hansom, MD · Principal investigator
  • Montréal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Rafik Tadros, MD PhD · Principal investigator
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval
    Québec, Quebec, Canada
    Recruiting
    • · Contactcrds@phri.ca · 905-521-2100
    • Christian Steinberg, MD · Principal investigator
  • Rigshospitalet
    Copenhagen, The Capital Region of Denmark 2100, Denmark
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Jacob Tfelt-Hansen, MD, DMSc · Principal investigator
  • Aarhus University Hospital
    Aarhus, DK-8200 N, Denmark
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Henrik Jensen, MD · Principal investigator
  • CHU de Bordeaux
    Bordeaux, New Aquitaine 33404, France
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Frédéric Sacher, MD · Principal investigator
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Ziv Dadon, MD · Principal investigator
  • Oxford University Hospitals
    Oxford, Oxfordshire 0X3 9DU, United Kingdom
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Julian Ormerod, BM, Bch, FRCP · Principal investigator
  • City St George's, University of London
    London, EC1V 0HB, United Kingdom
    Recruiting
    • Project Manager · Contactcrds@phri.ca · 905-521-2100
    • Mark Specterman, MBBS, MRCP, PhD · Principal investigator
08

References and documents

Publications

  • Sun B, Yao J, Ni M, Wei J, Zhong X, Guo W, Zhang L, Wang R, Belke D, Chen YX, Lieve KVV, Broendberg AK, Roston TM, Blankoff I, Kammeraad JA, von Alvensleben JC, Lazarte J, Vallmitjana A, Bohne LJ, Rose RA, Benitez R, Hove-Madsen L, Napolitano C, Hegele RA, Fill M, Sanatani S, Wilde AAM, Roberts JD, Priori SG, Jensen HK, Chen SRW. Cardiac ryanodine receptor calcium release deficiency syndrome. Sci Transl Med. 2021 Feb 3;13(579):eaba7287. doi: 10.1126/scitranslmed.aba7287. PubMed 33536282 ↗
  • Roston TM, Wei J, Guo W, Li Y, Zhong X, Wang R, Estillore JP, Peltenburg PJ, Noguer FRI, Till J, Eckhardt LL, Orland KM, Hamilton R, LaPage MJ, Krahn AD, Tadros R, Vinocur JM, Kallas D, Franciosi S, Roberts JD, Wilde AAM, Jensen HK, Sanatani S, Chen SRW. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiol. 2022 Jan 1;7(1):84-92. doi: 10.1001/jamacardio.2021.4458. PubMed 34730774 ↗
  • Li Y, Wei J, Guo W, Sun B, Estillore JP, Wang R, Yoruk A, Roston TM, Sanatani S, Wilde AAM, Gollob MH, Roberts JD, Tseng ZH, Jensen HK, Chen SRW. Human RyR2 (Ryanodine Receptor 2) Loss-of-Function Mutations: Clinical Phenotypes and In Vitro Characterization. Circ Arrhythm Electrophysiol. 2021 Sep;14(9):e010013. doi: 10.1161/CIRCEP.121.010013. Epub 2021 Sep 1. PubMed 34546788 ↗
  • Ormerod JOM, Ormondroyd E, Li Y, Taylor J, Wei J, Guo W, Wang R, Sarton CNS, McGuire K, Dreau HMP, Taylor JC, Ginks MR, Rajappan K, Chen SRW, Watkins H. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. Circ Genom Precis Med. 2022 Feb;15(1):e003589. doi: 10.1161/CIRCGEN.121.003589. Epub 2021 Dec 24. PubMed 34949103 ↗
  • Ni M, Li Y, Wei J, Song Z, Wang H, Yao J, Chen YX, Belke D, Estillore JP, Wang R, Vallmitjana A, Benitez R, Hove-Madsen L, Feng W, Chen J, Roston TM, Sanatani S, Lehman A, Chen SRW. Increased Ca2+ Transient Underlies RyR2-Related Left Ventricular Noncompaction. Circ Res. 2023 Jul 7;133(2):177-192. doi: 10.1161/CIRCRESAHA.123.322504. Epub 2023 Jun 16. PubMed 37325910 ↗
  • Ni M, Dadon Z, Ormerod JOM, Saenen J, Hoeksema WF, Antiperovitch P, Tadros R, Christiansen MK, Steinberg C, Arnaud M, Tian S, Sun B, Estillore JP, Wang R, Khan HR, Roston TM, Mazzanti A, Giudicessi JR, Siontis KC, Alak A, Acosta JG, Divakara Menon SM, Tan NS, van der Werf C, Nazer B, Vivekanantham H, Pandya T, Cunningham J, Gula LJ, Wong JA, Amit G, Scheinman MM, Krahn AD, Ackerman MJ, Priori SG, Gollob MH, Healey JS, Sacher F, Nof E, Glikson M, Wilde AAM, Watkins H, Jensen HK, Postema PG, Belhassen B, Chen SRW, Roberts JD. A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome. JAMA. 2024 Jul 16;332(3):204-213. doi: 10.1001/jama.2024.8599. PubMed 38900490 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Dec 2050, 313 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 18, 2024
StartActual
Nov 21, 2024
Primary completionEst.
Dec 31, 2050
CompletionEst.
Dec 31, 2050
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Alberta Health Services · Edmonton, Canada
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    1 site added
    Show site
    • Alberta Health Services · Edmonton, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06508164
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Nov 21, 2024
Primary completion
Dec 31, 2050 (estimated)
Completion
Dec 31, 2050 (estimated)
Last update
Sep 28, 2026

Study contacts

Jason D Roberts, MD MAS
Contact
crds@phri.ca
905-297-3479 ext. 40632
Thomas M Roston, MD, PhD
study chair · University of British Columbia
Jason D Roberts, MD MAS
principal investigator · McMaster University
SR Wayne Chen, PhD
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion